MCID: EWN002
MIFTS: 48

Ewing's Family of Tumors

Categories: Bone diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Ewing's Family of Tumors

MalaCards integrated aliases for Ewing's Family of Tumors:

Name: Ewing's Family of Tumors 53
Neuroectodermal Tumor, Primitive 72
Primitive Neuroectodermal Tumor 53
Ewing Family of Tumors 53
Ewing's Tumor of Bone 53
Extraosseous Ewing's 53
Askin's Tumor 53

Classifications:



External Ids:

UMLS 72 C0206663

Summaries for Ewing's Family of Tumors

MalaCards based summary : Ewing's Family of Tumors, also known as neuroectodermal tumor, primitive, is related to cellular myxoid liposarcoma and extraskeletal ewing sarcoma. An important gene associated with Ewing's Family of Tumors is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are GPCR Pathway and PEDF Induced Signaling. The drugs Temozolomide and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and kidney, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Related Diseases for Ewing's Family of Tumors

Diseases related to Ewing's Family of Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 446)
# Related Disease Score Top Affiliating Genes
1 cellular myxoid liposarcoma 31.0 EWSR1 CDK4
2 extraskeletal ewing sarcoma 30.9 FLI1 EWSR1
3 grade iii astrocytoma 30.8 CDKN2B CDKN2A CDK4
4 liposarcoma 30.7 EWSR1 CDKN2A CDK4
5 malignant peripheral nerve sheath tumor 30.3 KIT CDKN2A CDK4
6 gastrointestinal stromal tumor 30.2 KITLG KIT CDKN2A
7 neurofibroma 30.0 KITLG KIT CDKN2A
8 mesenchymal cell neoplasm 30.0 KIT EWSR1
9 papilloma 29.8 RB1 CDKN2B CDKN2A
10 glioblastoma multiforme 29.4 RB1 MTOR ERBB2 CDKN2A CDK4
11 small cell cancer of the lung 29.1 RB1 KIT CSF3 CDKN2A
12 glioblastoma 29.0 RB1 MTOR ERBB2 CDKN2B CDKN2A CDK4
13 ewing sarcoma 29.0 RB1 KITLG KIT FLI1 FAS EWSR1
14 adenocarcinoma 28.9 RB1 KIT ERBB2 CDKN2A CDK4
15 leukemia, acute myeloid 28.7 MTOR KITLG KIT CSF3 CDKN2B
16 leukemia, chronic myeloid 28.6 KITLG KIT EPO CSF3 CDKN2B
17 bladder urothelial carcinoma 28.0 RB1 MTOR KIT FAS ERBB2
18 sarcoma 27.8 RB1 MTOR KIT FLI1 EWSR1 CDK4
19 endometrial cancer 27.8 RB1 MTOR KIT ERBB2 CDKN2A CDK4
20 myelodysplastic syndrome 27.8 KITLG KIT FAS EPOR EPO CSF3
21 supratentorial primitive neuroectodermal tumor 12.8
22 cerebral primitive neuroectodermal tumor 12.7
23 intracranial primitive neuroectodermal tumor 12.7
24 central nervous system primitive neuroectodermal tumor 12.6
25 primitive neuroectodermal tumor of the cervix uteri 12.6
26 askin's tumor 12.6
27 primitive neuroectodermal tumor of the corpus uteri 12.5
28 medulloblastoma 12.5
29 ewing sarcoma of bone 12.3
30 extraosseous ewing sarcoma 12.1
31 pineoblastoma 12.0
32 rhabdoid tumor predisposition syndrome 1 12.0
33 ependymoblastoma 11.8
34 spinal cord primitive neuroectodermal neoplasm 11.8
35 extraosseous ewings sarcoma-primitive neuroepithelial tumor 11.8
36 atypical teratoid rhabdoid tumor 11.8
37 cerebellopontine angle primitive neuroectodermal 11.8
38 bone peripheral neuroepithelioma 11.8
39 childhood supratentorial embryonal tumor, not otherwise specified 11.6
40 adult central nervous system primitive neuroectodermal neoplasm 11.5
41 childhood central nervous system primitive neuroectodermal neoplasm 11.5
42 rhabdoid tumor predisposition syndrome 2 11.5
43 infiltrating angiolipoma 10.6 CDKN2A CDK4
44 cornea cancer 10.6 CDKN2A CDK4
45 retinoblastoma 10.6
46 familial retinoblastoma 10.6
47 kidney fibrosarcoma 10.6 EWSR1 EPO
48 hydrocephalus 10.6
49 congenital hydrocephalus 10.6
50 astrocytoma 10.6

Graphical network of the top 20 diseases related to Ewing's Family of Tumors:



Diseases related to Ewing's Family of Tumors

Symptoms & Phenotypes for Ewing's Family of Tumors

GenomeRNAi Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.5 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.5 CDK4 KIT MTOR
3 Decreased substrate adherent cell growth GR00193-A-3 9.5 CDK4
4 Decreased substrate adherent cell growth GR00193-A-4 9.5 CDK4 KIT
5 Increased transferrin (TF) endocytosis GR00363-A 9.32 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2

MGI Mouse Phenotypes related to Ewing's Family of Tumors:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
2 cardiovascular system MP:0005385 10.35 CDK4 CDKN2A EPO EPOR ERBB2 FAS
3 hematopoietic system MP:0005397 10.35 CDK4 CDKN2A CDKN2B CSF3 EPO EPOR
4 immune system MP:0005387 10.33 CDK4 CDKN2A CDKN2B CSF3 EPO EPOR
5 homeostasis/metabolism MP:0005376 10.3 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
6 embryo MP:0005380 10.29 CDK4 CDKN2A EPO EPOR ERBB2 FLI1
7 endocrine/exocrine gland MP:0005379 10.28 CDK4 CDKN2A CDKN2B ERBB2 FAS FLI1
8 growth/size/body region MP:0005378 10.27 CDK4 CDKN2A EPOR ERBB2 FAS FLI1
9 mortality/aging MP:0010768 10.27 CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
10 integument MP:0010771 10.24 CDK4 CDKN2A CDKN2B CSF3 EPO ERBB2
11 liver/biliary system MP:0005370 10.16 CDK4 CDKN2A EPO EPOR FAS FLI1
12 digestive/alimentary MP:0005381 10.14 CDK4 CDKN2A ERBB2 FAS KIT KITLG
13 nervous system MP:0003631 10.13 CDK4 CDKN2A EPOR ERBB2 FAS FLI1
14 neoplasm MP:0002006 10.11 CDK4 CDKN2A CDKN2B ERBB2 FAS FLI1
15 muscle MP:0005369 10.08 CDK4 CDKN2A EPO ERBB2 FLI1 KIT
16 limbs/digits/tail MP:0005371 10 EPO ERBB2 FAS KIT KITLG RB1
17 normal MP:0002873 9.97 CDK4 EPO EPOR ERBB2 FAS KIT
18 no phenotypic analysis MP:0003012 9.88 CDKN2A CDKN2B EPOR KIT MTOR RB1
19 pigmentation MP:0001186 9.8 CDK4 CDKN2A FAS KIT KITLG RB1
20 renal/urinary system MP:0005367 9.8 CDK4 CDKN2B CSF3 FAS KIT MTOR
21 reproductive system MP:0005389 9.76 CDK4 CDKN2A CDKN2B ERBB2 FAS KIT
22 respiratory system MP:0005388 9.56 CDKN2A EPO EPOR ERBB2 FAS KIT
23 skeleton MP:0005390 9.23 CDKN2A EPO ERBB2 FAS KIT KITLG

Drugs & Therapeutics for Ewing's Family of Tumors

Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 210)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
2
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
3
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
6
Donepezil Approved Phase 3 120014-06-4 3152
7
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
8
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
15
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
16
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
17
Histamine Approved, Investigational Phase 3 51-45-6 774
18
Cyproheptadine Approved Phase 3 129-03-3 2913
19
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
20
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
23 Nucleic Acid Synthesis Inhibitors Phase 3
24 Anti-Infective Agents Phase 3
25 BB 1101 Phase 3
26 Central Nervous System Depressants Phase 3
27 Liver Extracts Phase 3
28 Antiemetics Phase 3
29 Peripheral Nervous System Agents Phase 3
30 Autonomic Agents Phase 3
31 Cola Phase 3
32 Analgesics Phase 3
33 Nootropic Agents Phase 3
34 Cholinesterase Inhibitors Phase 3
35 Cholinergic Agents Phase 3
36 Emetics Phase 3
37 Anesthetics, Intravenous Phase 3
38 Narcotics Phase 3
39 Analgesics, Opioid Phase 3
40 Adjuvants, Anesthesia Phase 3
41 Anesthetics, General Phase 3
42 Anesthetics Phase 3
43 Dermatologic Agents Phase 3
44 Adjuvants, Immunologic Phase 3
45 Retinol palmitate Phase 3
46 retinol Phase 3
47 Vitamins Phase 3
48 Keratolytic Agents Phase 3
49 Neurotransmitter Agents Phase 3
50 Gastrointestinal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 163)
# Name Status NCT ID Phase Drugs
1 Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors Unknown status NCT00179803 Phase 2, Phase 3
2 EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
3 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
4 Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
5 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
6 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
7 Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
8 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
9 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
12 Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients Active, not recruiting NCT00392327 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Isotretinoin;Vincristine Sulfate
13 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
14 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
15 The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
16 Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Non-Pineal Supratentorial Primitive Neuroectodermal Tumours Unknown status NCT00274911 Phase 2 cisplatin;lomustine;vincristine sulfate
17 Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
18 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
19 Phase II Randomized Multicenter Study of Everolimus as Maintenance Therapy for Metastatic Neuroendocrine Carcinoma With Pulmonary or Gastroenteropancreatic Origin Unknown status NCT02687958 Phase 2 Everolimus
20 Phase II Trial of Gleevec (STI571) in Therapy of Ewing's Family of Tumors and Desmoplastic Small Round Cell Tumors Completed NCT00062205 Phase 2 imatinib mesylate
21 A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric And Young Adult Patients With Ewing's Sarcoma (ES), Primitive Neuroectodermal Tumor (PNET), Or Desmoplastic Small Round Cell Tumor (DSRCT) Completed NCT00055952 Phase 2 exatecan mesylate
22 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
23 Phase II Study of Antineoplastons A10 and AS2-1 In Children With Primitive Neuroectodermal Tumors Completed NCT00003460 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
24 A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors Completed NCT00047177 Phase 2 Oxaliplatin
25 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
26 Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
27 Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2 Zalypsis
28 A Phase II Study of Continuous 21 Day Infusion of Topotecan (NSC # 609699) in Children With Relapsed Solid Tumors Completed NCT00003745 Phase 2 topotecan hydrochloride
29 A Phase II Study of Navelbine (Vinorelbine) In Children With Recurrent Or Refractory Malignancies Completed NCT00003234 Phase 2 vinorelbine tartrate
30 A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS Completed NCT00002825 Phase 2 docetaxel
31 Randomized Phase II Study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane With and Without ImmTher for Newly Diagnosed High Risk Ewing's Sarcoma Completed NCT00003667 Phase 2 cyclophosphamide;dexrazoxane hydrochloride;disaccharide tripeptide glycerol dipalmitoyl;doxorubicin hydrochloride;vincristine sulfate
32 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
33 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
34 A Phase I/II Study of 166Ho-DOTMP With Peripheral Blood Progenitor Cell Support for Refractory or Recurrent Ewing's Sarcoma Family of Tumors With Bone Disease Completed NCT00006234 Phase 1, Phase 2
35 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
36 INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY Completed NCT00002643 Phase 2 amifostine trihydrate;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
37 A Phase II Trial of a Chemotherapy Based Regimen of Intravenous Busulfan (Busulfex), Melphalan and Thiotepa as Myeloablative Regimen Followed by a T- Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant From and HLA-Compatible Donor in the Treatment of High Risk Ewing's Sarcoma Family Tumors Completed NCT00357396 Phase 2 busulfan;melphalan;thiotepa
38 A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
39 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
40 Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma Completed NCT00470275 Phase 2 cytarabine
41 Phase II Study of Irinotecan (CPT-11) in Children and Adolescents With High Risk Ewing's Sarcoma Completed NCT00276692 Phase 2 irinotecan hydrochloride
42 A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors Completed NCT00030667 Phase 2 imatinib mesylate
43 A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas Completed NCT00070109 Phase 2 trabectedin
44 Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support Completed NCT00003211 Phase 2 amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate
45 High-Dose Doxorubicin and Ifosfamide Followed by Melphalan and Cisplatin for Patients With High-Risk and Recurrent Sarcoma Completed NCT00002601 Phase 2 cisplatin;doxorubicin hydrochloride;ifosfamide;melphalan
46 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
47 Phase II Study of Antineoplastons A10 and AS2-1 in Children With Brain Tumors Completed NCT00003458 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
48 Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Brain Tumors. Completed NCT00003457 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
49 A Phase II Trial of Radiosurgery for 1 to 3 Newly Diagnosed Brain Metastases From Renal Cell, Melanoma and Sarcoma Completed NCT00003308 Phase 2
50 Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors Completed NCT00003241 Phase 2 phenylacetate

Search NIH Clinical Center for Ewing's Family of Tumors

Genetic Tests for Ewing's Family of Tumors

Anatomical Context for Ewing's Family of Tumors

MalaCards organs/tissues related to Ewing's Family of Tumors:

41
Brain, Bone, Kidney, Uterus, Lung, Spinal Cord, Bone Marrow

Publications for Ewing's Family of Tumors

Articles related to Ewing's Family of Tumors:

(show top 50) (show all 1975)
# Title Authors PMID Year
1
Primary Ewing Family of Tumor Arising in the Ovary: A Case Report. 38
30085939 2019
2
Ultrasonographic Findings of 1385 Adrenal Masses: A Retrospective Study of 1319 Benign and 66 Malignant Masses. 38
29194699 2019
3
Congenital cutaneous peripheral primitive neuroectodermal tumor/Ewing sarcoma: A rare case in a male neonate. 38
31429518 2019
4
Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis. 38
31423907 2019
5
[Nephrotic syndrome with primitive neuroectodermal tumor in a child]. 38
31352753 2019
6
Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors. 38
31352632 2019
7
Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survival. 38
31264356 2019
8
ZBTB16: A new biomarker for primitive neuroectodermal tumor element / Ewing sarcoma. 38
31326195 2019
9
Next-generation whole exome sequencing of glioblastoma with a primitive neuronal component. 38
30715630 2019
10
Infratentorial Glioblastoma Metastasis to Bone. 38
31356980 2019
11
Primitive Neuroectodermal Tumor of the Prostate with Notalgia and Paraplegia as the Initial Symptoms: A Case Report and Literature Review. 38
31314635 2019
12
Primitive Neuroectodermal Tumor in a Child with Human Immunodeficiency Virus Infection: A Rare Association. 38
31257424 2019
13
Medulloblastoma With Metastasis to the Jaw in a Child With Nevoid Basal Cell Carcinoma Syndrome: A Case Report. 38
31310734 2019
14
Ovarian primary primitive neuroectodermal tumor: a review of cases at PUMCH and in the published literature. 38
31217017 2019
15
Cytogenetic characterization of the malignant primitive neuroectodermal SK-PN-DW tumor cell line. 38
31046733 2019
16
Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. 38
31104192 2019
17
Pazopanib Confers a Progression-free Survival in a Patient with Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Lung. 38
30626819 2019
18
H3F3A-G34R mutant high grade neuroepithelial neoplasms with glial and dysplastic ganglion cell components. 38
31109382 2019
19
High grade sarcoma, with predominant neuroectodermal and minor embryonal rhabdomyosarcomatous tumor of the uterus: A case report. 38
31032392 2019
20
Image-guided Fine Needle Aspiration Cytology of Intrathoracic Lesions. 38
30992646 2019
21
Atypical presentation of a germline APC mutation in a child with supratentorial primitive neuroectodermal tumor. 38
30511453 2019
22
Primitive neuroectodermal tumors: a clinical and radiological analysis of six cases. 38
31143663 2019
23
Primary peripheral neuroectodermal tumor (PNET) of the adrenal gland: a rare entity. 38
31128035 2019
24
Intraneural Ewing Sarcoma of Fibular Nerve: Case Report, Radiologic Findings and Review of Literature. 38
30579008 2019
25
Intracranial Neoplasms in the First Year of Life: Results of a Third Cohort of Patients From a Single Institution. 38
29617945 2019
26
Experience with 102 Frameless Stereotactic Biopsies Using the neuromate Robotic Device. 38
30500594 2019
27
Ewing's sarcoma of the sinonasal tract with orbital extension: a rare case report and literature review. 38
30949328 2019
28
Qualitative and quantitative CECT features for differentiating renal primitive neuroectodermal tumor from the renal cell carcinoma and its subtypes. 38
30362816 2019
29
Radiosurgery or hypofractionated stereotactic radiotherapy after craniospinal irradiation in children and adults with medulloblastoma and ependymoma. 38
30515559 2019
30
Rapidly Expanding Pediatric Post Radiation Brainstem Cavernoma Presenting with Singultus. 38
31058040 2019
31
Primitive myxoid mesenchymal tumor of infancy with brain metastasis: first reported case. 38
30178176 2019
32
Long-term survival of a patient with a large adrenal primitive neuroectodermal tumor: A case report. 38
30746375 2019
33
Primary Intra-abdominal Ewing's Sarcoma in Adults: A Multimodality Imaging Spectrum. 38
30642618 2019
34
Peripheral primitive neuroectodermal tumor associated with paraneoplastic Cushing's syndrome: The rare case. 38
30581565 2019
35
Primitive neuroectodermal tumor of kidney with Level III inferior vena cava thrombus. 38
30787583 2019
36
Diagnosis of NUT carcinoma of lung origin by next-generation sequencing: case report and review of the literature. 38
30307375 2019
37
Spinal Peripheral Primitive Neuroectodermal Tumors: A Radiological Analysis of Ten Cases. 38
29492943 2019
38
Extraskeletal Ewing's sarcoma/peripheral primitive neuroectodermal tumor of the small bowel presenting with gastrointestinal perforation. 38
31417299 2019
39
Ultrasensitive quantification of tumor mRNAs in extracellular vesicles with an integrated microfluidic digital analysis chip. 38
30474100 2018
40
Ewing-Like Sarcoma: A Case of a Primary Cutaneous Primitive Neuroectodermal Tumor With Atypical Immunohistochemistry and Lack of Fusion Oncogene Detection. 38
30067549 2018
41
A Clinicopathologic and Molecular Analysis of 34 Mediastinal Germ Cell Tumors Suggesting Different Modes of Teratoma Development. 38
30256256 2018
42
Primary spinal primitive neuroectodermal tumor: A single center series with literature review. 38
30561250 2018
43
Clinical Applications of Quantitative 3-Dimensional MRI Analysis for Pediatric Embryonal Brain Tumors. 38
30108003 2018
44
Outcomes in children with central nervous system tumors disseminated at presentation: a large single-center experience. 38
29938304 2018
45
A Comparison of the Histopathologic Growth Patterns Between Non-Merkel Cell Small Round Blue Cell Tumors and Merkel Cell Carcinoma. 38
30045067 2018
46
Successful Novel Treatment of a Paraspinal Primitive Neuroectodermal Tumor with Predominantly Glial Differentiation: A 3-Year Follow-Up After Surgery, Intensity-Modulated Radiation Therapy and Oral Temozolomide. 38
30077020 2018
47
Intracranial Peripheral Primitive Neuroectodermal Tumor Arising from the Clivus with Intracranial Metastasis in an Elderly Woman: Case Report and Review of the Literature. 38
30144615 2018
48
Ewing's sarcoma of kidney in a 60-year-old patient with local recurrence: A rare occurrence. 38
30488867 2018
49
Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. 38
30332335 2018
50
Scrotal Peripheral Primitive Neuroectodermal Tumor. 38
30374281 2018

Variations for Ewing's Family of Tumors

Expression for Ewing's Family of Tumors

Search GEO for disease gene expression data for Ewing's Family of Tumors.

Pathways for Ewing's Family of Tumors

Pathways related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 RB1 KITLG KIT ERBB2 EPOR CDKN2B
2
Show member pathways
13.58 MTOR KIT FAS ERBB2 EPOR EPO
3
Show member pathways
13.53 RB1 MTOR KITLG KIT FAS ERBB2
4
Show member pathways
13.28 MTOR KITLG KIT FAS ERBB2 EPOR
5
Show member pathways
13.04 RB1 MTOR EPO CDKN2B CDKN2A CDK4
6
Show member pathways
12.88 RB1 MTOR FAS CDKN2A CDK4
7
Show member pathways
12.84 KITLG KIT FAS EPOR EPO
8
Show member pathways
12.72 RB1 MTOR KIT ERBB2 CDKN2A CDK4
9 12.67 KITLG KIT FAS ERBB2
10
Show member pathways
12.64 MTOR KITLG KIT ERBB2
11
Show member pathways
12.53 RB1 MTOR ERBB2 CDKN2B CDKN2A CDK4
12
Show member pathways
12.49 RB1 CDKN2B CDKN2A CDK4
13
Show member pathways
12.49 RB1 MTOR KITLG KIT FAS ERBB2
14 12.48 KITLG KIT FLI1 FAS
15
Show member pathways
12.47 RB1 MTOR KIT ERBB2 CDKN2B CDKN2A
16
Show member pathways
12.33 MTOR EPOR EPO CSF3
17
Show member pathways
12.3 RB1 FAS CDKN2A CDK4
18
Show member pathways
12.3 MTOR KITLG KIT ERBB2 EPOR
19 12.29 RB1 CDKN2B CDKN2A CDK4
20
Show member pathways
12.27 RB1 CDKN2B CDKN2A CDK4
21 12.23 RB1 KITLG CDKN2B CDKN2A CDK4
22 12.2 RB1 CDKN2B CDKN2A CDK4
23
Show member pathways
12.14 RB1 MTOR ERBB2 CDK4
24
Show member pathways
12.11 RB1 CDKN2B CDKN2A CDK4
25 12.09 RB1 MTOR KITLG KIT FAS ERBB2
26 12.06 RB1 MTOR CDK4
27
Show member pathways
12.06 KITLG KIT EPOR EPO
28 12.04 KITLG KIT ERBB2
29 12.01 RB1 MTOR CDKN2B CDKN2A CDK4
30 11.89 KITLG KIT EPO CSF3
31 11.88 RB1 MTOR CDKN2A
32 11.88 MTOR ERBB2 EPO
33 11.86 RB1 MTOR CDKN2A CDK4
34 11.81 MTOR EPOR EPO
35 11.8 RB1 CDKN2B CDK4
36 11.68 FAS ERBB2 CDKN2A
37 11.64 RB1 MTOR CDK4
38 11.64 MTOR KIT ERBB2
39 11.6 RB1 ERBB2 CDKN2A CDK4
40 11.54 KITLG KIT EPOR EPO CSF3
41 11.47 RB1 FAS CDKN2A
42 11.43 KITLG KIT EPO
43 11.4 RB1 CDKN2B CDK4
44 11.35 KITLG FLI1 EPO CSF3
45 11.22 CDKN2B CDKN2A CDK4
46 11.04 RB1 CDKN2A
47 10.94 KITLG KIT ERBB2 EPOR CSF3
48 10.89 KITLG KIT

GO Terms for Ewing's Family of Tumors

Biological processes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 MTOR KIT ERBB2 CDKN2A
2 positive regulation of cell proliferation GO:0008284 9.83 KITLG KIT EPO CSF3 CDK4
3 G1/S transition of mitotic cell cycle GO:0000082 9.7 RB1 CDKN2A CDK4
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 MTOR KITLG CSF3
5 negative regulation of apoptotic process GO:0043066 9.63 KITLG FAS EPO
6 positive regulation of Ras protein signal transduction GO:0046579 9.58 KITLG EPO
7 negative regulation of phosphorylation GO:0042326 9.58 CDKN2B CDKN2A
8 positive regulation of translation GO:0045727 9.58 MTOR ERBB2 CDK4
9 embryonic hemopoiesis GO:0035162 9.57 KITLG KIT
10 megakaryocyte development GO:0035855 9.56 KIT FLI1
11 response to hyperoxia GO:0055093 9.55 EPO CDK4
12 positive regulation of MAP kinase activity GO:0043406 9.5 KITLG KIT ERBB2
13 somatic stem cell division GO:0048103 9.48 KIT CDKN2A
14 cell cycle arrest GO:0007050 9.46 RB1 MTOR CDKN2B CDKN2A
15 ectopic germ cell programmed cell death GO:0035234 9.37 KITLG KIT
16 positive regulation of protein kinase B signaling GO:0051897 9.35 MTOR KITLG KIT ERBB2 CSF3
17 negative regulation of immature T cell proliferation in thymus GO:0033088 9.26 ERBB2 CDKN2A
18 positive regulation of transcription by RNA polymerase III GO:0045945 9.21 MTOR
19 erythropoietin-mediated signaling pathway GO:0038162 8.8 KIT EPOR EPO
20 signal transduction GO:0007165 10.08 KITLG KIT FAS ERBB2 EPOR EPO

Molecular functions related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.97 RB1 MTOR KITLG KIT FLI1 FAS
2 nucleotide binding GO:0000166 9.56 MTOR KIT ERBB2 CDK4
3 identical protein binding GO:0042802 9.1 RB1 MTOR FAS EWSR1 ERBB2 EPOR
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN2B CDKN2A

Sources for Ewing's Family of Tumors

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....